


## PharmaLedger Year 2 – First Generation Blockchain Platform Deployed

**December 13, 2021** – PharmaLedger, a public-private project with 29 members under the Innovative Medicines Initiative (IMI), has successfully concluded its second year. Despite the current COVID-19 challenges, PharmaLedger has made significant progress towards its goal to deliver a common and widely trusted blockchain-based platform with reference implementations that bring value to patients and ecosystem partners. In 2022, as the project enters its final year, PharmaLedger will further develop its solutions, confirm the value proposition with stakeholders and prepare for ultimate adoption through a post-project sustainability function.

### PharmaLedger's Key 2021 Achievements:

- Platform architecture foundation is in place and being tested:
  - Deployment of a **cross-company decentralized blockchain network with six nodes** to test the platform and the electronic Product Information (ePI or eLeaflet) application. The PharmaLedger network will be extended and will include onboarding of new partners and manufacturers outside the consortium at the end of 2022, when the operational environment is launched.
  - Further development and implementation in all use cases of **Open Data Sharing Units (OpenDSU)**, an innovative off-chain storage and data exchange framework that leverages Edge & Enterprise Wallets and blockchain technology agnostic anchoring to enable scalability while ensuring self-sovereign data control, will continue.
- Technical development of demonstrators for the eight use cases across three domains:
  - Supply Chain:** electronic Product Information (ePI or eLeaflet), Clinical Supply Chain, Finished Goods Traceability, and Anti-Counterfeiting (Detecting Falsified Medicines packaging)
  - Clinical Trials:** Clinical Trial Recruitment and eConsent (Informed Consent Form)
  - Health Data:** Medical device IoT (Internet of Things) and Personalized Medicine
- Growing brand recognition and engagement with over 4,000 social community members, participation in over 60 internal and external events and 29 news mentions.
- Collaboration with industry members and service providers outside of the consortium for development, testing and piloting of solutions; demonstrating that PharmaLedger's open-source, technology agnostic, ecosystem-oriented approach is viable. An example is the integration of different authentication feature technologies from TrueMed® and AlpVision Cryptoglyph® together with INCM (the Portuguese Mint, a consortium member) into a common app for the Anti-Counterfeiting use case.
- An IMI review confirmed that the €22 million project has completed all activities, deliverables and milestones to date.



*Current PharmaLedger blockchain network - the PharmaLedger node represents public partners in the consortium*

## Outlook

PharmaLedger will transition from focusing on “Development and Deployment in 2021,” to “Validation and Sustainability,” in 2022. The key objectives for next year are:

- Use case demonstrator evaluation, including validation of blockchain’s value proposition
- Publishing results-related scientific documentation
- Development of system lifecycle documentation and “playbooks” for adoption
- Continuous platform improvement and broad promotion including engagement with 3<sup>rd</sup> parties
- Implementation of and transition to the post-project governance and operating model
- Active engagement with pharma companies and other stakeholders, inviting them to join the Trusted Ecosystem Journey

## About PharmaLedger

Sponsored by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the Horizon 2020 programme, PharmaLedger is a 36-month project that brings together 12 global pharmaceutical companies and 17 public and private entities: including technical, legal, regulatory, academia, research, and patient representative organisations. The goal of the project is to provide a widely trusted platform that supports the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that benefits the entire ecosystem, from manufacturers to patients.

### Consortium Members:

- Universidad Politécnica de Madrid (Project Coordinator) - ES
- Novartis (Industry Leader) – CH
- Projecto Desenvolvimento Manutenção Formação e Consultadoria, Lda - PT
- RomSoft SRL - RO
- Arteevo Technologies Ltd. - IL
- Technovative Solutions Ltd. - UK
- EKON Modeling Software Systems Ltd. IL
- Centre for Research and Technology Hellas - GR
- AbbVie INC. - NL
- AstraZeneca AB - SE
- Bayer Aktiengesellschaft - DE
- Boehringer-Ingelheim GmbH - DE
- GlaxoSmithKline Research and Development Limited - UK
- Janssen Pharmaceutica NV - BE
- Merck Sharp & Dohme Corp - US
- Novo Nordisk A/S - DK
- Pfizer Ltd - UK
- F.Hoffmann-La Roche AG - CH
- UCB Biopharma SPRL - BE
- Katholieke Universiteit Leuven - BE
- Onorach Ltd - UK
- National Research and Development Institute for Cryogenics and Isotopic Technologies - RO
- University Hospital Würzburg - DE
- Democritus University of Thrace - GR
- Hospital do Espírito Santo de Évora - PT
- Ospedale Pediatrico Bambino Gesù - IT
- Imprensa Nacional-Casa da Moeda - PT
- European Patient Forum - BE
- European Forum for Good Clinical Practice - BE

[www.imi.europa.eu](http://www.imi.europa.eu)

*Disclaimer: this communication reflects the author's view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained therein. Mention of third parties and products does not constitute an endorsement by any of the consortium members.*

### Industry Leader



### Coordinator

